

Repeat Radiation in the Brain: Managing Patients With Locally Recurrent Glioma



Daniel M. Trifiletti, MD,* Timothy D. Malouff, MD,* Susan L. McGovern, MD, PhD,[†] Shiao-Pei Weathers, MD,[‡] Tony J.C. Wang, MD,^{§,||} Andrew B. Lassman, MD,^{||,¶} Daniel P. Cahill, MD,[#] Helen A Shih, MD,^{**} and Paul D. Brown, MD^{††}

> Treatment of recurrent gliomas is especially challenging, as many of these patients have previously been treated with extensive surgery, radiation, or systemic therapy. Due to this, the optimum therapy for patients with recurrent glioma is controversial, with widely variable practice patterns. In this opinion piece, a multidisciplinary panel of experts provides rationale for their treatment approach in a patient with recurrent glioma following subtotal resection with adjuvant chemoradiation for an anaplastic astrocytoma. In summary, the consensus of the panel was to recommend re-resection if possible with hypofractionated radiotherapy schedules, with re-irradiation and systemic therapy as directed by a multidisciplinary team through repeat analysis of the tumor specimen for an updated mutational burden.

Semin Radiat Oncol 30:218-222 © 2020 Elsevier Inc. All rights reserved.

^{*}Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL.

- [†]Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
- [‡]Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
- [§]Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY.
- Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY.
- ¹Department of Neurology, Columbia University Irving Medical Center, New York, NY.
- [#]Department of Neurosurgery, Massachusetts General Hospital, Boston, MA.
- **Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
- ^{††}Department of Radiation Oncology, Mayo Clinic, Rochester, MN.
- Conflicts of interest: DMT: Dr. Trifiletti reports support from Novocure for unrelated clinical trial research.
- PDB: Dr. Brown reports personal fees from UpToDate, outside the submitted work.

- TJW: Dr. Wang reports personal fees and non-financial support from Abb-Vie, personal fees from AstraZeneca, personal fees and non-financial support from Elekta, personal fees and non-financial support from Merck, personal fees from Doximity, personal fees from Wolters Kluwer, personal fees and non-financial support from Novocure, personal fees and non-financial support from RTOG Foundation, personal fees from Cancer Panels, outside the submitted work.
- ABL: Dr. Lassman reports grants and non-financial support from Novartis, during the conduct of the study; personal fees and non-financial support from Orbus, grants, personal fees and non-financial support from Karyopharm, personal fees and non-financial support from NW Biotherapeutics, grants and non-financial support from Oncoceutics, personal fees

and non-financial support from Agios, personal fees and non-financial support from Celgene, personal fees and non-financial support from Novocure, non-financial support from Tocagen, non-financial support from BMS, grants, personal fees and non-financial support from Kadmon, grants and non-financial support from Genentech/Roche, grants and nonfinancial support from Amgen, grants and non-financial support from Millenium, non-financial support from Celldex, grants and non-financial support from Novartis, grants and non-financial support from Pfizer, non-financial support from Keryx/Aeterna Zentaris, grants and non-financial support from VBI Vaccines, grants and non-financial support from Beigene, personal fees from Bioclinica as an expert blinded independent reviewer of clinical and imaging data for a BMS-sponsored trial, personal fees from prIME Oncology, personal fees and non-financial support from Sapience, personal fees from WebMD, personal fees and non-financial support from Physicians' Education Resource, personal fees from Cortice, grants, personal fees and non-financial support from AbbVie, personal fees and non-financial support from Forma, personal fees and non-financial support from Bayer, grants and non-financial support from Global Coalition for Adaptive Research, personal fees and non-financial support from American Society of Clinical Oncology, grants and non-financial support from QED, grants, personal fees and non-financial support from NCI, non-financial support from New York University, grants and nonfinancial support from NRG Oncology/RTOG-Foundations, grants from UCLA, grants from Northwestern University, grants from James S. McDonnell Foundation, non-financial support from Yale University, nonfinancial support from Radiological Society of North America, non-financial support from FDA, personal fees from Italian Foundation for Cancer Research, personal fees and non-financial support from Abbott Molecular, personal fees from Elsevier, outside the submitted work.

Address reprint requests to Daniel M. Trifiletti, MD, Department of Radiation Oncology, Mayo Clinic, 4500 San Pablo Road South, Jacksonville, FL 32224. E-mail: trifiletti.daniel@mayo.edu

SLM has received grant support from the Dr. Marnie Rose Foundation.

SPW has received clinical trial support from Genentech and Mundipharma.